In addition to BCR/ABL1 oncogene, other genes involved in CML LSCs survival such as EZH2 can make LSCs more susceptible to TKIs by using CRISPR/Cas9-mediated gene editing [140]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.